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Purpose: Lung cancer is the leading cause of cancer death in
Australia, but little is known about how Australian patients with this
disease are managed.
Methods: Lung cancer patients diagnosed from November 1, 2001
to December 31, 2002 were identified through the population-based
New South Wales Central Cancer Registry. Information was col-
lected on diagnosis, staging, referrals, and treatment. Cross-tabula-
tions and logistic regression examined factors related to not receiv-
ing cancer-specific therapy.
Results: There were 2931 potentially eligible patients registered by
the Central Cancer Registry and completed questionnaires were
obtained for 1812 patients (62%); median age 71 years and 66%
men. The pathology was non-small cell in 71%, small cell in 15%
and not confirmed in 13% of patients. Eleven percent of patients did
not see a lung cancer specialist and 33% received no cancer-specific
therapy after initial diagnosis. Treatment utilization rates were 17%
for surgery, 39% for radiotherapy, and 30% for chemotherapy.
Factors significantly associated with having no cancer-specific ther-
apy included female gender, older age, weight loss, poorer perfor-
mance status, advanced or unknown disease stage, and consultation
with a low patient volume lung cancer specialist or a non-lung
cancer specialist. The median survival was 172 days and 2-year
crude survival was 17%.
Conclusions: Treatment patterns were in broad concordance with
present national guidelines. Nevertheless, a significant proportion of
lung cancer patients did not receive cancer-specific therapy. Treat-
ment decisions should be multidisciplinary and decision-makers
should include experienced lung cancer specialists.
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Lung cancer is an important cause of morbidity and mor-tality in Australia. It is the fourth commonest cancer in
Australian male and female patients, and the leading cause of
cancer death.1,2 The 5-year relative survival is only 14%.2
Despite this, there are few data on how lung cancer is
managed in Australia.
Hypothetical scenarios have demonstrated variability in
treatment recommendations for lung cancer.3,4 Surveys of
respiratory physicians and thoracic surgeons have found dif-
ferences in survival estimates, treatment recommendations,
and referral patterns.5 Differences have been documented in
the treatment recommendations of Australian specialists com-
pared with their international counterparts.6 “What happens
to people with this disease depends largely on the personal
beliefs of their doctors and the fate of the individual patient
is determined by accidents of geography and patterns of
referral that lead him or her to one doctor’s office rather than
another.”7
Existing data show variability in practice and subopti-
mal utilization of treatment in Australia. In 1993, a Victorian
study of lung cancer revealed a wide range of patient man-
agement and lack of adherence to published international
guidelines.8 In 1996, pathologic confirmation of diagnoses
ranged from 80 to 91% and treatment utilization varied from
55 to 78% across three health areas in New South Wales
(NSW). Patients in an outer metropolitan/rural health area
were significantly less likely to have treatment.9 The results
from these studies are dated and a complete picture of lung
cancer management was not available for NSW, the largest
state in Australia. Also, it was difficult to determine from
these studies the reasons why patients did not have treatment.
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We conducted a population-based lung cancer patterns
of care study in NSW to assess how current practice com-
pared with that recommended in national guidelines and to
identify factors associated with treatment given.
METHODS
The study population comprised NSW residents diag-
nosed with primary lung cancer between November 1, 2001
and December 31, 2002. Mesothelioma, carcinoid tumors and
sarcomas were excluded. Eligible cases were ascertained
from notifications to the NSW Central Cancer Registry
(CCR) which meets the data quality standards for inclusion in
“Cancer Incidence in Five Continents” compiled by the
International Agency for Cancer Research. Rates of histo-
logic verification are high (87%) and notification by death
certificate only are low (1.4%). Also, the mortality to inci-
dence ratio of 37% is in good agreement with the 5-year
relative survival of 63%.10
Where possible, patients were asked to give consent to
obtain information about their lung cancer from their doctors.
If the patient had died, specific ethics committee approval
allowed treatment data to be obtained directly from doctors.
This study was approved by the Ethics Committees of The
Cancer Council NSW and Area Health Services where field
collection was undertaken.
Doctors were sent questionnaires seeking information
on the patient and treatment administered under their care
relating to (1) patient demographics, clinical characteristics
(weight loss, Eastern Cooperative Oncology Group [ECOG]
status, number of primary tumors, site of primary tumor,
morphology, tumor, node, metastasis stage for non-small cell
lung cancers (NSCLC), small cell lung cancer (SCLC) stage,
basis for staging, and comorbidities), investigations, referrals,
and initial management; (2) surgery; (3) radiotherapy; and (4)
chemotherapy. When required, a trained field officer was
provided to extract information from medical records.
SCLC was staged using the Veteran’s Administration
staging system.11 Tumor, node, metastasis staging was used
for NSCLC and cancers with no pathologic confirmation
(NPC).12 Performance status was based on the ECOG scale
that rates patients on a five-point scale from being able to
carry out normal activities (ECOG 0) to being bed bound
(ECOG 4).13 The questionnaire included a description of the
scale so that clinicians could assign a score. Where ECOG
status was not stated in medical records, the field officer
assigned a score based on available information in the
records. Each patient’s place of residence was coded accord-
ing to the rurality of the health area they lived in at diagnosis
(Metropolitan, Other Urban, Rural). Doctors’ experience in
relation to lung cancer was classified using a combination of
medical specialty and lung cancer patient volume during the
study period. Comorbidities were documented if the addi-
tional condition was likely to impact on the decision to
receive cancer-specific treatment.
Data were entered into an Access database and ana-
lyzed using SAS statistical software. Cross-tabulations and
logistic regression examined factors related to not receiving
cancer-specific therapy. Variables statistically significantly
related to not receiving treatment in the bivariate analysis
together with variables considered to be clinically important
were included in the logistic models. Kaplan-Meier survival
curves summarized survival up to 2 years after diagnosis.
RESULTS
There were 2931 potentially eligible patients identified
by the CCR for whom treatment information could be sought
in 2126 (73%). Information was not sought when either the
patient or the doctor could not be contacted (n  198) or
refused consent (n  483), or the CCR notification was
received after the end of data collection (n  124). The study
sample comprised 1812 patients (62% of potentially eligible
patients) for whom diagnosis and treatment data were avail-
able. Reasons for lack of diagnosis and treatment data in-
cluded doctor refused to provide data, medical record could
not be found, or data received after close of the study. There
were no significant differences in demographic and disease
variables between the study sample and all CCR cases diag-
nosed during the study period (data not shown).
Median age at diagnosis was 71 years and similar in men
and women and 66% of patients were men (Table 1). Less than
half of all patients lived in a metropolitan health area (48%).
At initial diagnosis, the majority of patients had
NSCLC (71%), 15% had SCLC, and there was NPC of cancer
at diagnosis for 13% (Table 2). Of the latter, pathologic
confirmation was not attempted by the diagnosing clinician in
44%, attempted but cancer tissue not obtained in 37%, and
16% of patients refused. Clinical evidence alone (clinical
examination and imaging) was used to stage 71% of patients,
whereas pathologic evidence (surgery and tissue confirmation
of nodal or other metastases) was also used for 27%. Weight
loss and comorbidities were recorded for 81% and 92% of
patients, respectively. Of these 40% had weight loss (10%
in 3 months) at presentation and 73% had at least one
comorbid condition likely to affect treatment, the most com-
mon being chronic airflow limitation (CAL) (38%), ischemic
TABLE 1. Participant’s Demographic Profile (n  1812)
n %
Sex
Male 1195 66
Female 617 34
Age (yrs)
0–59 353 19
60–69 478 26
70–79 701 39
80 275 15
Unknown/missing 5 0.3
Health area at diagnosisa
Metropolitan 867 48
Other urban 481 26
Rural 464 26
a Metropolitan-Central Sydney, South Eastern Sydney, South Western Sydney,
Wentworth, Western Sydney, Northern Sydney; Other Urban-Central Coast, Hunter,
Illawarra; Rural-Far West, Greater Murray, Macquarie, Mid North Coast, Mid Western,
New England, Northern Rivers, Southern.
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heart disease (19%), and diabetes (10%). The proportion with
comorbidities was similar in male and female patients (75%
versus 72%). Male patients had higher rates of CAL (40%
versus 34%), but similar rates of ischemic heart disease (19%
versus 16%) and diabetes (11% versus 9%). Overall 74% had
good performance status (ECOG 0–2).
Respiratory physicians, cardiothoracic surgeons, medi-
cal oncologists, and radiation oncologists were considered to
be lung cancer specialists. Eighty-nine percent of patients
saw a lung cancer specialist at some time. Over half saw a
respiratory physician (54%), with most consultations occur-
ring at initial presentation (98%). Of those who saw a respi-
ratory physician at initial presentation 90% were referred,
86% of these were referred to a cardiothoracic surgeon or an
oncologist. Approximately two thirds (64%) of patients saw a
treating lung cancer specialist at some time during initial
treatment: radiation oncologist 47%, medical oncologist 45%,
and cardiothoracic surgeon 23%.
The 11% of patients (n  207) who did not see a lung
cancer specialist were more likely to: be older (median age 74
years versus 70 years, p  0.001); have poorer performance
status (35% versus 17% with ECOG 3–4, p  0.001); live in
a rural health area (21% versus 9% and 8% for metropolitan
and other urban, respectively; p  0.001); have a higher
proportion of unknown comorbidities (14% versus 7%, p 
0.001); have NPC lung cancer (37% versus 10%, p  0.001);
and have cancer of unknown stage (19% versus 6%, p 
0.001). There were no gender differences.
Pulmonary function tests were done in 47% and imag-
ing in 98% of patients. Imaging included chest computed
tomography in 90%, brain computed tomography in 29%,
bone scan in 33%, and positron emission tomography (PET)
scans in 17% of cases. Fifty percent underwent bronchoscopy
and 4% had mediastinoscopy. A pathologic specimen was
obtained in 91% of patients and the diagnosis of lung cancer was
confirmed in 87%; lung cancer remained the preferred diagnosis
for those in whom the specimen did not show cancer.
Cancer-specific therapy, defined as surgery, chemother-
apy, or radiotherapy was given to 67% of patients and 33%
received none of these after initial diagnosis. The utilization
rate for surgery was 17%, radiotherapy 39%, and chemother-
apy 30%. Treatment by pathology and stage are shown in
Tables 3 through 5.
Approximately three-quarters of patients with NSCLC
received treatment and 20% of stage I to 31% of stage IV did
not receive treatment (Table 3). Surgery was the most com-
mon intervention for stage I disease. Surgery and radiother-
apy alone were equally common treatments for patients with
stage II disease. Patients with stage III or IV disease were
most likely to receive radiotherapy alone.
Most patients with limited stage SCLC had chemother-
apy and radiotherapy (43%), whereas those with extensive
disease usually had chemotherapy alone (37%) (Table 4).
Anticancer treatment was not given to 25% and 31% of
limited and extensive stage SCLC patients, respectively.
Stage I patients with NPC lung cancer were most likely to
have surgery (42%) (Table 5). The remaining NPC patients
were most likely to have no treatment, ranging from 65% for
stage III to 71% for stage IV.
A total of 598 patients did not receive cancer-specific
therapy. Factors statistically significantly and independently
associated with no treatment were female gender, aged 70
years or more, weight loss, ECOG score 2, advanced or
unknown stage, seeing a doctor with a low patient volume
TABLE 2. Participant’s Clinical Profile (n  1812)
n % n %
ECOG score Stage at diagnosis
0 504 28 SCLC 278 15
1 519 29 Limited 83 5
2 313 17 Extensive 189 10
3 238 13 Unknown/missing 6 0.3
4 94 5 NSCLC 1290 71
Unknown/missing 144 7 Stage I 286 16
Number of comorbidities Stage II 90 5
None 334 18 Stage III 308 17
1 511 28 Stage IV 527 29
2 345 19 Unknown/missing 79 4
3 222 12 NPC 237 13
4 or more 250 14 Stage I 57 3
Unknown/missing 150 8 Stage II 12 1
Weight loss at presentationa Stage III 31 2
Weight loss 869 33 Stage IV 73 4
No weight loss 602 48 Unknown/missing 64 4
Unknown/missing 341 19 Pathology unknownb 7 0.4
a 10% in 3 months at presentation.
b Data on pathology were missing for seven patients.
ECOG, Eastern Cooperative Oncology Group; SCLC, small cell lung cancer; NSCLC, non-small cell lung Cancer; NPC, not
pathologically confirmed.
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(15 patients seen in the survey equating to one or fewer a
month) or not seeing a lung cancer specialist, and residence in
“other urban” area health services (neither metropolitan Syd-
ney nor rural) (Table 6). Comorbidities and histologic type
(data not shown) were not independently associated with not
receiving treatment.
Of the 593 patients who had an initial presentation and
diagnosis questionnaire, and received no cancer-specific ther-
apy, approximately 95% were considered inoperable at initial
diagnosis. Nevertheless, 71% were referred for further treat-
ment and/or evaluation. After adjusting for significant prog-
nostic factors, variables associated with no referral after
TABLE 3. Initial Treatment of NSCLC by Stage in NSW 2001–2002
Stage I
(n  286)
Stage II
(n  90)
Stage III
(n  308)
Stage IV
(n  527)
Unknown
stage
(n  79) Total
n %a n %a n %a n %a n %a n %a
Surgery 139 49 22 24 13 4 7 1 19 24 200 16
RT 47 16 20 22 97 31 173 33 6 8 343 27
Chemo 9 3 7 8 35 11 94 18 11 14 156 12
Chemo and RT 9 3 7 8 57 19 79 15 8 10 160 12
Chemo and surgery 5 2 3 3 5 2 2 0 3 4 18 1
Surgery and RT 13 5 8 9 6 2 6 1 2 3 35 3
Chemo and RT and surgery 7 2 0 0 10 3 0 0 1 1 18 1
No treatment 57 20 23 26 85 28 166 31 29 37 360 28
a Calculated as percentage of stage category.
Chemo, chemotherapy; RT, radiotherapy.
TABLE 4. Initial Treatment of SCLC by Stage in NSW 2001–2002
Limited
(n  83)
Extensive
(n  189)
Unknown
(n  6) Total
n %a n %a n %a n %a
Surgery 1 1 0 0 0 0 1 0.4
RT 2 2 13 7 0 0 15 5
Chemo 21 25 70 37 1 17 92 33
Chemo and RT 36 43 47 25 1 17 84 30
Chemo and surgery 1 1 0 0 0 0 1 0.4
Surgery and RT 0 0 0 0 0 0 0 0
Chemo and RT and surgery 1 1 1 1 0 0 2 0.7
No treatment 21 25 58 31 4 67 83 30
a Calculated as percentage of stage category.
Chemo, chemotherapy; RT, radiotherapy.
TABLE 5. Initial Treatment of NPC Lung Cancer by Stage in NSW 2001–2002
Stage I
(n  57)
Stage II
(n  12)
Stage III
(n  31)
Stage IV
(n  73)
Unknown
stage
(n  64) Total
n %a n %a n %a n %a n %a n %a
Surgery 24 42 0 0 0 0 0 0 7 11 31 13
RT 9 16 4 33 8 26 17 23 4 6 42 18
Chemo 1 2 0 0 0 0 1 1 1 2 3 1.3
Chemo and RT 0 0 0 0 3 10 3 4 0 0 6 3
Chemo and surgery 1 2 0 0 0 0 0 0 0 0 1 0.4
Surgery and RT 2 4 0 0 0 0 0 0 1 2 3 1.3
Chemo and RT and surgery 1 2 0 0 0 0 0 0 0 0 1 0.4
No treatment 19 33 8 67 20 65 52 71 51 80 150 63
a Calculated as percentage of stage category.
NPC, not pathologically confirmation; Chemo, chemotherapy; RT, radiotherapy.
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initial diagnosis (data not shown) included increasing age
(odds ratio (OR)  1.04 per year of age, p  0.001); resident
in a rural health area relative to a metropolitan health area
(OR  1.69, p  0.047) and diagnosis with unknown stage
relative to locoregional spread (OR  1.75, p  0.04).
Of all the patients who did not receive cancer-specific
therapy, 138 were potentially curable and may have benefited
from curative treatment (Figure 1). These patients had good
performance status (ECOG 0–2) and either NSCLC stage I,
II, or III disease (n  120), or limited SCLC (n  18) at
TABLE 6. Multivariable Analysis of Factors Related to Not Having Treatment for all Lung
Cancer Patients with Treatment Data (n  1812)
n Not Treated (%)
Odds
Ratioa
95%
Confidence
Interval p
Gender 0.0129
Male 1195 31 1 Ref.
Female 617 37 1.40 1.08 1.82
Age 0.0001
0–59 353 16 1 Ref.
60–69 478 25 1.33 0.87 2.04
70–79 701 37 2.32 1.56 3.43
80 275 57 4.02 2.54 6.37
Unknown 5 20 0.20 0.01 6.56
Health Areab 0.0081
Metropolitan 867 29 1 Ref.
Other urban 481 35 1.51 1.11 2.05
Rural 464 39 0.92 0.66 1.27
Stage 0.0001
Locoregional 867 27 1 Ref.
Metastatic 789 35 1.57 1.19 2.06
Unknown 156 57 3.05 1.89 4.92
ECOGc 0.0001
0 504 16 1 Ref.
1 519 27 1.44 0.98 2.11
2 313 43 2.22 1.47 3.35
3 238 57 3.42 2.19 5.35
4 94 69 5.58 3.02 10.29
Unknown 144 32 1.74 1.00 3.02
Weight lossd 0.0001
No 869 23 1 Ref.
Yes 602 40 1.51 1.03 2.21
Unknown 341 46 1.96 1.47 2.62
Number of comorbidities 0.24
None 334 18 1 Ref.
1 511 31 1.29 0.84 1.98
2 345 35 1.47 0.94 2.30
3 222 39 1.64 1.00 2.70
4 or more 250 42 1.76 1.09 2.85
Unknown 150 45 1.31 0.75 2.31
Lung cancer specialist (LCS) and volume 0.0001
LCS 20 patients 1196 21 1 Ref.
LCS consulted between 15 and 19 patients 108 23 0.80 0.47 1.34
LCS consulted between 10 and 14 patients 115 36 1.90 1.20 3.01
LCS consulted between 5 and 9 patients 129 40 2.80 1.80 4.34
LCS consulted between 1 and 4 patients 56 61 5.33 2.83 10.02
No lung cancer specialist 208 96 110.98 51.77 237.89
a Odds ratio adjusted for all variables in the table.
b Metropolitan-Central Sydney, South Eastern Sydney, South Western Sydney, Wentworth, Western Sydney, Northern
Sydney; Other Urban-Central Coast, Hunter, Illawarra; Rural-Far West, Greater Murray, Macquarie, Mid North Coast, Mid
Western, New England, Northern Rivers, Southern.
c Eastern Cooperative Oncology Group.
d 10% in 3 months at presentation.
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initial diagnosis. Over half of these patients were diagnosed
by a lung cancer specialist (54%) and 80% were referred for
treatment; but only 37% went on to see a treating clinician.
Twenty percent of these patients refused treatment. One third
of these refusals were among patients who were not referred.
Overall in the study sample of 1812 patients, 5% (n  99)
decided against any treatment.
The median survival was 172 days or approximately 6
months (95% CI: 152–186 days) and the 2-year crude sur-
vival was 17%.
DISCUSSION
This study is the first comprehensive population-based
lung cancer patterns of care study in NSW and the most
recent study in Australia. The study attempted to capture the
patient’s journey from diagnosis to initial treatment, and
explore the reasons for the care given.
The demographic characteristics of the patients were
representative of a typical Western lung cancer population
with a preponderance of men and a median age at diagnosis
of 71 years.8,14,15 Approximately three-quarters of the sample
had an identifiable comorbid condition likely to impact on
treatment, most usually CAL. This is higher than 66% of
patients with serious concomitant illnesses reported in a
Dutch lung cancer population.16
Pathologic testing was performed in 91% and con-
firmed the diagnosis in 87% of cases. This is similar to the
1993 Victorian study and a previous NSW study for 1993–
1996 where pathologic confirmation was obtained in 88% and
91% respectively.8,17 These are higher than figures derived
empirically in guidelines from Scotland and the United King-
FIGURE 1. Pathway of potentially
curable patients.
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dom.18,19 Only 9% did not undergo any pathology testing.
This seems reasonable as pathology would not have influ-
enced management for those with comorbidities that contra-
indicated biopsy, who may have been unfit for treatment or
who refused further investigation and management. Similar
to other lung cancer populations, approximately two thirds of
all patients presented with locally advanced or metastatic
disease.16
Lung cancer is managed by a multitude of health care
providers as different and multiple treatment modalities may
be used for each stage of disease. In this study, 89% consulted
a lung cancer specialist. This is comparable to Scotland
(87%) and higher than in Yorkshire (75%).15,20 Only 54% of
patients consulted a respiratory physician when one would
assume that they are the main specialists diagnosing lung
cancer. This referral rate is identical to that in Yorkshire but
lower than in Scotland where three-quarters of patients saw a
respiratory physician. Referrals to surgeons were similar,
23% in NSW versus 19 to 21% in Yorkshire and Scotland, as
were referrals to oncologists ranging from 45 to 47% in NSW
versus 45 to 53% in Scotland and Yorkshire.
Scottish guidelines state that all patients with suspected
lung cancer should be referred to a respiratory physician and
UK COIN guidelines indicate that 95% of nonsurgical pa-
tients should be discussed in a multidisciplinary team.18,19
Assuming that specialist referral is required as a minimum for
multidisciplinary care, given that 11% of patients did not see
a lung cancer specialist of any type, neither of these bench-
marks was reached in this study.
As described previously in South Western Sydney,
Victoria, and South Australia, one third of patients did not
receive any anticancer treatment after diagnosis.8,17,21 Since
the former studies, readily accessible lung cancer guidelines
have been published and there is now good evidence that
radiotherapy and chemotherapy can improve survival and
quality of life.22,23 Nevertheless, there have been no measur-
able changes in treatment of lung cancer in NSW. The rate of
no treatment is lower than that reported in Scotland (43%)
and Ireland (50%) but higher than in the United States where
it varies from 15% for SCLC to 20% for NSCLC.14,15,24
Patient factors that were associated with lack of treat-
ment included female gender, increasing age, and poorer
performance status. Although poorer performance status may
be a valid reason for not treating a patient, older age alone is
not. Numerous studies have confirmed the benefits of treating
the elderly and studies have identified treatments without
excessive toxicity.25–27 Increased utilization of active treat-
ment has resulted in significantly improved survival in the
elderly with lung cancer.28 The association of female gender
with no treatment has not been described in other studies and
needs further exploration.15,17
Stage had a small impact on the no treatment rates for
NSCLC and SCLC. This ranged from one in three patients
with stage III and IV NSCLC and extensive SCLC to one in
five patients with stage I NSCLC. One would expect the
rate of no treatment to increase with stage as the intent of
treatment changes from curative to palliative. It may be
argued that immediate treatment for palliation is not re-
quired if the patient is asymptomatic. Nevertheless, this
would be true for a minority of patients, as most present
with symptoms and the proportion with symptoms in-
creases with disease stage.24
The presence of comorbidity did not independently
affect likelihood of treatment. This may have been because
most patients had good performance status despite the pres-
ence of comorbidities. Similarly in a Dutch study, the pres-
ence of comorbid conditions influenced surgical resection
rates in operable NSCLC but not treatment for locally ad-
vanced or metastatic NSCLC or SCLC.16
Patients with weight loss were less likely to have
treatment. Most randomized trials of curative treatment ex-
clude patients with greater than 5 or 10% weight loss as it is
taken to be a marker of systemic disease, particularly in the
pre-PET era, where patients experience no survival benefit
from treatment. Nevertheless, there are conflicting data on
whether this is an independent prognostic factor for sur-
vival and whether it should be used to make treatment
decisions in isolation.29 This is particularly true now that
more accurate staging investigations such as PET scans
may be used to exclude patients with metastatic disease
from curative treatment.
Specialist care has been associated with greater access
to curative treatment and significantly better survival.15,30 In
this study, health provider characteristics influenced treat-
ment. Patients referred to a lung cancer specialist, especially
one with higher caseload, were more likely to receive treat-
ment. This may reflect a selection bias with patients thought
not to be fit enough for treatment not being referred to
treating specialists. Nevertheless, this assumes that the non-
referring doctor has sufficient experience to make that deci-
sion and this may not be valid as surveys of different
specialty types have reported a wide variety of opinions on
the management of lung cancer.5 Other studies have shown
that specialists who saw fewer lung cancer patients per year
were less likely to be aware of the benefits of nonsurgical
treatment and to offer any treatment.4,5 Specialty type, case-
load, year of training, and country of practice have all been
found to influence various aspects of care.4,5
The study has some limitations. Treatment data were
obtained for only 62% of eligible patients despite consider-
able efforts to gain doctor and patient consent and obtaining
ethics approval to acquire treatment information directly from
doctors of deceased cases. Although the study sample was
unlikely to be materially biased, as it did not differ greatly
from all lung cancer patients diagnosed during the study
period on the demographic (age and sex) and disease (stage,
morphology, method of diagnosis) characteristics, there were
some statistically significant differences between participants
and nonparticipants: nonparticipants were more likely to have
early stage disease (p  0.0001) and a histologically con-
firmed diagnosis (p  0.0001) (data not shown). Although
these differences could have a small effect on overall treat-
ment patterns, we see no reason why they should affect the
representativeness of stage-specific treatment patterns.
It might also be argued that the data are now 5 years old
and that practice might have changed, especially with the
Journal of Thoracic Oncology • Volume 3, Number 8, August 2008 Lung Cancer Care in New South Wales Australia
Copyright © 2008 by the International Association for the Study of Lung Cancer 877
publication of the Australian Lung Cancer Guidelines in 2004
with a corresponding information card for General Practitio-
ners.29 Nevertheless, changes are slow to occur in practice as
evidenced by the similar proportion of patients not being
treated in 1993, 1996, and 2002.8,31 Moreover, the utilization
rates for chemotherapy and radiotherapy showed only modest
increases from 21% and 33%, respectively in 1996 to 25%
and 37% in 2002, despite new evidence supporting the use of
these modalities during that period. Although there is also
new evidence supporting the use of adjuvant chemotherapy, it
applies only to a relatively small patient group and would not
be expected to change utilization rates of chemotherapy as
much as would its widespread adoption in the palliative
setting. Further data will need to be collected to determine
how pervasive these changes have become. The findings of
this study are therefore likely to be relevant to current
practice.
Another possible limitation is this study’s focus on the
individual doctors who patients consulted or were referred to.
In a multidisciplinary setting, it is possible that some cases
may have been presented, discussed, and treatment not rec-
ommended without the patient ever having been referred
directly to a specialist. Our approach to data collection may
have missed these cases.
A significant proportion of lung cancer patients in NSW
did not receive any treatment initially. The majority of pa-
tients presented with locally advanced or metastatic disease in
which treatment can improve a patient’s quality of life and
prolong survival, although it may not be curative. Neverthe-
less, a proportion of patients with early stage, potentially
curable NSCLC, did not receive treatment. In part, this was
because of patient refusal of treatment; but health care pro-
vider characteristics also influenced the likelihood of not
receiving treatment. Patients of specialists seeing few lung
cancer patients and non-lung cancer specialists were more
likely not to be treated. Lung cancer survival in NSW can
only improve if treatment utilization increases. This requires
education of patients about all treatment options and ensuring
that patients are at least discussed with high volume lung
cancer specialists or, preferably, receive experienced multi-
disciplinary team management.
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